News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Agenus to present new insights from Botensilimab Programs at ASCO 2025
Agenus/LinkedIn
Apr 24, 2025, 05:36

Agenus to present new insights from Botensilimab Programs at ASCO 2025

Agenus shared a post on LinkedIn:

“The Agenus team is heading back to this year’s ASCO Annual Meeting.

We look forward to engaging with the oncology community and sharing new insights from our botensilimab programs.

Learn more about the upcoming presentations.”

Agenus ASCO ASCO Annual Meeting botensilimab cancer OncoDaily Oncology
Special Coverage
Science
Sep 2, 2025, 20:26
Yinghui Li: Novel lncRNA PLUM Drives Chemoresistance in Multiple Myeloma Through PRC2 Pathway
Societies
Sep 2, 2025, 18:53
A Busy Month of Global Healthcare Innovation and Conferences - EHFF
Voices
Sep 2, 2025, 18:26
Tong Yin Shared Details of AstraZeneca’s ECP Symposium on Breast Cancer Diagnostics
Voices
Sep 2, 2025, 17:36
Tackling Hepatitis and Its Connection to Liver Cancer - European Cancer Organisation
Blog Posts
Sep 2, 2025, 17:24
Launching the 10th LuCE Report: Marking a Decade of Evidence from Lived Experience
Career Updates
Sep 2, 2025, 17:15
Joaquim Bosch-Barrera Begins New Role as Associate Adjunct Professor at ICO
Blog Posts
Sep 2, 2025, 17:08
Aria’s Story and the Fight for Better Treatments for Childhood Cancer - Children's Cancer Institute
Science
Sep 2, 2025, 16:54
Rishabh Jain: A-BRAVE Lesson - A "Negative" Trial Shifts the Conversation
Voices
Sep 2, 2025, 16:41
Improving Communication in Advanced Cancer Care - ABC Global Alliance
Insight
Sep 2, 2025, 16:36
Advocate Aurora Health Hiring Vice President for Cancer National Service Line in Wisconsin
Voices
Sep 2, 2025, 16:27
Stephen V Liu: BellRinger - 25 Miles on October 25th
Science
Sep 2, 2025, 16:26
Aleix Prat: Biomarker-Driven Patient Selection Key in HR+/HER2+ Metastatic Breast Cancer